Mohamed Hassanein
Overview
Explore the profile of Mohamed Hassanein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
2006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vazvaei-Smith F, Li W, Barnaby O, Bhardwaj S, Dong J, Dumont C, et al.
AAPS J
. 2025 Mar;
27(2):57.
PMID: 40069400
The analysis of Non-Liquid Matrices (NLMs) can provide key information on many aspects in drug discovery and development. These include but are not limited to drug uptake and distribution, engagement...
2.
Sriperumbuduri S, Atari M, Hassanein M
Indian J Nephrol
. 2025 Mar;
35(2):307-308.
PMID: 40060077
No abstract available.
3.
Hassanein M, Alawadi F, AlKadhim I, Aly H, Bajawi D, Cinar T, et al.
Diabetes Ther
. 2025 Feb;
PMID: 40016571
Introduction: Oral semaglutide, a glucagon-like peptide 1 receptor agonist, requires administration on an empty stomach with up to 120 mL of water, followed by no intake of food, beverages, or...
4.
Elom H, Hegazy Y, Lerma E, Hassanein M
Indian J Nephrol
. 2025 Jan;
35(1):21-28.
PMID: 39872265
Introduction: Acute kidney injury (AKI) is a frequent complication of chronic liver disease (CLD) contributing to high morbidity and mortality worldwide. While liver transplantation (LT) has shown favorable outcomes, early...
5.
Almahmeed W, Alabadla Z, Al Awadi F, Alrohmaihi D, AlShamiri M, Elbadawi H, et al.
Adv Ther
. 2025 Jan;
42(3):1340-1359.
PMID: 39841371
Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease...
6.
Ebrahimi N, Glassock R, Gholizadeh Ghozloujeh Z, Hassanein M, Narayan M, Abdipour A, et al.
Kidney Int Rep
. 2025 Jan;
10(1):267-268.
PMID: 39810780
No abstract available.
7.
Alessa T, Al Awadi F, Al Kaabi J, Al Mamari A, Al Ozairi E, Alromaihi D, et al.
Diabetes Metab Syndr Obes
. 2024 Dec;
17:4791-4802.
PMID: 39712240
Prediabetes is the first stage of a continuum that extends through the diagnosis of clinical type 2 diabetes towards long-standing diabetes with multiple comorbidities. The diagnosis of prediabetes provides an...
8.
Hassanein M, Malek R, Al Sifri S, Sahay R, Buyukbese M, Djaballah K, et al.
Diabetes Ther
. 2024 Sep;
15(11):2309-2322.
PMID: 39249672
Introduction: The aim of this work was to assess the safety and effectiveness of concomitant iGlarLixi and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use in adults with type 2 diabetes (T2D) who...
9.
Hassanein M, Zainudin S, Shaikh S, Shaltout I, Malek R, Buyukbese M, et al.
Curr Med Res Opin
. 2024 Jul;
40(9):1515-1523.
PMID: 39076065
Background: Managing diabetes during Ramadan fasting is a challenge due lifestyle changes. We described the characteristics and patterns of care for type 2 diabetes mellitus (T2DM) during Ramadan 2020 and...
10.
Kinhikar A, Hassanein M, Harman J, Soderstrom C, Honrine K, Lavelle A, et al.
AAPS J
. 2024 Jul;
26(5):87.
PMID: 39060472
Western blot (WB) assays are routinely used for detection and quantification of biomarkers. Although assay validation to measure biomarkers in complex matrices has become a mainstay process for ligand binding...